Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide vs Tirzepatide CV Outcomes

A matched cohort found similar cardiovascular outcomes with semaglutide and tirzepatide, but the observational design cannot prove equivalence.

Why we wrote this. A nonsignificant observational comparison can be mistaken for proof of equal benefit. We separate that finding from randomized evidence.

In this article (5 sections)
  1. What the cohort study compared
  2. The two cardiovascular results
  3. Why this is not a randomized trial
  4. How randomized evidence differs
  5. What we do not know yet

A retrospective study of health records found no statistically significant difference in cardiovascular outcomes between semaglutide and tirzepatide among matched adults with overweight or obesity, established atherosclerotic cardiovascular disease, and no diabetes. After matching, each treatment group contained 5,665 people. The result is an observational association, not proof that the two medicines are equivalent.[1]

The researchers used TriNetX electronic health records and followed patients for different lengths of time. They reported no significant difference for either of two composite cardiovascular endpoints or for any component examined separately.[1] A randomized head-to-head cardiovascular outcomes trial would be needed to make a stronger cause-and-effect comparison.

What the cohort study compared

The study included adults aged 45 or older with a body mass index of at least 27 and documented atherosclerotic cardiovascular disease, often shortened to ASCVD. ASCVD covers disease caused by plaque buildup in coronary and cerebral arteries as well as arteries in the limbs. Anyone with diabetes was excluded. The index treatment was semaglutide 2.4 mg or tirzepatide at any recorded dose, first prescribed between January 2016 and January 2025.[1]

Before matching, the records contained 9,780 semaglutide users and 5,665 tirzepatide users. Propensity-score matching paired patients using age and other illnesses plus concurrent medicines, leaving 5,665 in each group. Matching can reduce measured differences between groups. It cannot balance factors that were missing or poorly recorded.[1]

Follow-up also differed. Mean follow-up was 497 days for semaglutide and 380 days for tirzepatide, while the medians were 453 and 350 days. The authors used time-to-event models that account for each person's observed time at risk, but they still listed shorter follow-up and possible calendar-time bias among the study's limits.[1]

The two cardiovascular results

The broader five-point composite counted all-cause death, myocardial infarction, ischemic stroke, heart-failure exacerbation, or coronary revascularization. It occurred in 19.5% of semaglutide users and 17.1% of tirzepatide users. The hazard ratio comparing semaglutide with tirzepatide was 1.03, with a 95% confidence interval from 0.94 to 1.12 and a p value of 0.53.[1]

The narrower three-point composite counted all-cause death, myocardial infarction, or ischemic stroke. It occurred in 17.4% and 15.4% of the groups, respectively. The hazard ratio was 1.04, with a 95% confidence interval from 0.95 to 1.14 and a p value of 0.42. Neither confidence interval excluded no difference, and none of the individual outcomes differed significantly.[1]

The raw percentages and the hazard ratios answer different questions. Percentages describe how often coded events appeared during unequal follow-up. Hazard ratios compare event rates over observed time. More importantly, a nonsignificant result does not establish that two treatments are interchangeable. The authors make that warning explicit.[1]

Why this is not a randomized trial

Treatment was not assigned by researchers. Clinicians and patients chose a medicine in ordinary care, so access and prescribing preference may have affected both treatment and outcomes. Illness severity, adherence, and unrecorded health differences could also matter. The database did not provide achieved dose or longitudinal weight change, nor did it track persistence and discontinuation in enough detail. Tirzepatide doses were pooled because dose-level data were not consistently available.[1]

Outcomes were identified from diagnosis and procedure codes rather than an independent committee reviewing each event. The authors noted possible misclassification and possible event-rate overestimation. They also could not display numbers at risk beneath the survival curves because TriNetX did not supply them. These constraints do not erase the result, but they narrow what it can support.[1]

How randomized evidence differs

SELECT provides randomized evidence for semaglutide against placebo, not against tirzepatide. It enrolled 17,604 adults with pre-existing cardiovascular disease, overweight or obesity, and no diabetes. Cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 6.5% assigned semaglutide and 8.0% assigned placebo over a mean 39.8 months of follow-up, for a hazard ratio of 0.80.[2]

SURMOUNT-5 directly randomized tirzepatide against semaglutide in 751 adults with obesity and no diabetes, but its primary endpoint was body-weight change at 72 weeks. Tirzepatide produced greater mean weight loss, 20.2% versus 13.7%. The trial did not test whether either medicine prevented more major cardiovascular events.[3]

A weight-loss advantage cannot be converted into a cardiovascular-event advantage without event evidence. The new cohort study addresses actual coded cardiovascular outcomes in a relevant high-risk population, yet its nonrandom design cannot supply the causal certainty that SELECT provides for semaglutide versus placebo.[1][2][3]

What we do not know yet

This analysis does not show that semaglutide and tirzepatide have equal cardiovascular effects. It shows that this matched electronic-record comparison did not detect a statistically significant difference during relatively short and unequal follow-up. Dose uncertainty and coding errors remain, as do residual confounding and different treatment eras.[1]

The unresolved question needs a prospective randomized trial that assigns the two medicines directly, follows patients long enough to accumulate cardiovascular events, and uses blinded event adjudication. Until such a trial reports, treatment choices should not be based on this cohort alone. The semaglutide evidence page and tirzepatide evidence page keep each medicine's randomized and regulatory evidence separate.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Did semaglutide and tirzepatide have the same cardiovascular outcomes?

The matched cohort found no statistically significant difference in its composite or individual outcomes. That does not prove equivalence because treatment was not randomized and important unmeasured differences may remain.

How many people were included?

After propensity-score matching, the analysis included 5,665 semaglutide users and 5,665 tirzepatide users. All were at least 45, had overweight or obesity and ASCVD, and did not have diabetes.

Was this a head-to-head randomized trial?

No. It was a retrospective TriNetX electronic-health-record study. Researchers matched recorded patient characteristics, but they did not assign treatment and could not remove unmeasured confounding.

Does greater weight loss mean fewer cardiovascular events?

Not necessarily. SURMOUNT-5 found greater weight loss with tirzepatide than semaglutide, but it was designed around weight change rather than cardiovascular events. Event benefits require direct outcome evidence.

Sources

  1. [1]Doma M, Ramadan A, Yazdanpanah MH, et al. Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and ASCVD without diabetes. Am Heart J Plus. 2026. PMID 43022342; PMCID PMC13755453.Tier 1 · primary↩
  2. [2]Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID 37952131.Tier 1 · primary↩
  3. [3]Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. PMID 40353578.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars